Tandem inhibition of PKC in diαβetic nephropathy: It takes two to tango?

Diabetes

Volumn 62, Issue 4, 2013, Pages 1010-1011

  Thallas Bonke, Vicki ^a,b   Cooper, Mark E ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 4; FIBRONECTIN; NEPHRIN; PERLECAN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C EPSILON; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALBUMINURIA; BASEMENT MEMBRANE; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; GLOMERULUS FILTRATION RATE; HUMAN; IN VIVO STUDY; KIDNEY FUNCTION; MESANGIUM CELL; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD FLOW; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TREATMENT DURATION; UPREGULATION;

ANIMALS; DIABETIC NEPHROPATHIES; MALE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA;

EID: 84875454013     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1666     Document Type: Note

References (23)

1. Menne J, Shushakova N, Bartels J, et al. Dual inhibition of classical protein kinase C-a and protein kinase C-b isoforms protects against experimental murine diabetic nephropathy. Diabetes 2013;62:1167-1174
2. Kang N, Alexander G, Park JK, et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 1999; 56:1737-1750
3. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866
4. Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004;53:2921-2930
5. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996;93:11047-11052
6. Osicka TM, Yu Y, Panagiotopoulos S, et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000;49:87-93
7. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl. 2007;(Suppl.):S49-S53
8. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008;57:460-469
9. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. J Clin Invest 1989;83:1667-1675
10. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731
11. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000;14:439-447
12. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003;52:512-518
13. Bakris GL. Protein kinase C-beta inhibition: a promise not yet fulfilled. Clin J Am Soc Nephrol 2007;2:619-620
14. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW, PKC-DRS, PKCDMES, and PKC-DRS 2 Study Groups. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007;2:631-636
15. Kikkawa R, Haneda M, Uzu T, Koya D, Sugimoto T, Shigeta Y. Translocation of protein kinase C alpha and zeta in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994;37:838-841
16. Li PF, Maasch C, Haller H, Dietz R, von Harsdorf R. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 1999;100:967-973
17. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996;273:788-791
18. Menne J, Park JK, Boehne M, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004;53:2101-2109
19. Menne J, Meier M, Park JK, et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 2006;70:1456-1462
20. Meier M, Park JK, Overheu D, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 2007;56:346-345
21. Ohshiro Y, Ma RC, Yasuda Y, et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006;55:3112-3120
22. Meier M, Menne J, Park JK, Haller H. Nailing down PKC isoform specificity in diabetic nephropathy two's company, three's a crowd. Nephrol Dial Transplant 2007;22:2421-2425
23. Meier M, Menne J, Park JK, et al. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 2007;18:1190-1198